Contraception. Safety and efficacy have been established in women between 18 and 40 years of age.
Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women's health, biosimilars and established brands.
Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange .
Merck announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its women’s health, biosimilars and established brands businesses into a standalone, publicly-traded company, Organon.If all conditions are met, the separation is on track for completion late in the second quarter of 2021.
Retina Implant AG has announced the publication of data from the Company's global clinical trial involving seven sites across five...
Retina Implant AG's wireless subretinal implant technology, the Alpha IMS, has received CE Mark approval in the EU to treat...
Intarcia Therapeutics, Inc., announced that the FDA has issued a Complete Response Letter (CRL) for ITCA 650 (exenatide implant) for...
HD LifeSciences has received FDA 510(k) clearance for its Hive ALIF standalone lumbar interbody fusion system, an adjustable spinal implant. The implant technology enables surgeons to choose between integrated zero-profile fixation or anterior plating and can be adjusted prior to implantation to better fit patient anatomy. The Hive ALIF system offers surgeons a number of configurations for height, width, depth and lordotic choices.
Vascular Dynamics announced European results of the company�s first-in-human trial of its Mobius HD implant in resistant hypertension has been...